Rein Therapeutics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 10

Employees

  • Stock Symbol
  • RNTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.36
  • (As of Thursday Closing)

Rein Therapeutics General Information

Description

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Contact Information

Website
www.reintx.com
Formerly Known As
Renegade Therapeutics, Aileron Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12407 North Mopac Expressway
  • Suite 250 Number 390
  • Austin, TX 78758
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 12407 North Mopac Expressway
  • Suite 250 Number 390
  • Austin, TX 78758
  • United States

Rein Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rein Therapeutics Stock Performance

As of 19-Nov-2026, Rein Therapeutics’s stock price is $0.36. Its current market cap is $31.7M with 86.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.36 $0.36 $0.28 - $2.10 $31.7M 86.3M 586K -$1.51

Rein Therapeutics Financials Summary

As of 30-Sep-2026, Rein Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 73,717 71,449 77,185 2,826
Revenue 0 0 0 0
EBITDA (50,429) (50,582) (64,364) (15,957)
Net Income (49,717) (49,871) (62,883) (15,732)
Total Assets 59,430 24,158 62,190 106,008
Total Debt 48
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rein Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatm
Drug Discovery
Austin, TX
10 As of 2025

Plymouth Meeting, PA
 

Florham Park, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rein Therapeutics Competitors (115)

One of Rein Therapeutics’s 115 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
XBiotech Corporation Austin, TX
Zealand Pharma Formerly VC-backed Soborg, Denmark
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 115 competitors. Get the full list »

Rein Therapeutics Patents

Rein Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4719450-A2 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Pending 30-May-2023
AU-2023305611-A1 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Pending 12-Jul-2022
EP-4554605-A2 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Pending 12-Jul-2022
EP-4554605-A4 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Pending 12-Jul-2022
AU-2022371643-A1 Modified caveolin-1 peptides for the treatment of chronic kidney disease Pending 22-Oct-2021 A61K38/177
To view Rein Therapeutics’s complete patent history, request access »

Rein Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rein Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Acquisitions (1)

Rein Therapeutics’s most recent deal was a Merger/Acquisition with Lung Therapeutics. The deal was made on 31-Oct-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lung Therapeutics 31-Oct-2023 Merger/Acquisition Drug Discovery
To view Rein Therapeutics’s complete acquisitions history, request access »

Rein Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.28 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Rein Therapeutics’s complete esg history, request access »

Rein Therapeutics FAQs

  • When was Rein Therapeutics founded?

    Rein Therapeutics was founded in 2001.

  • Where is Rein Therapeutics headquartered?

    Rein Therapeutics is headquartered in Austin, TX.

  • What is the size of Rein Therapeutics?

    Rein Therapeutics has 10 total employees.

  • What industry is Rein Therapeutics in?

    Rein Therapeutics’s primary industry is Drug Discovery.

  • Is Rein Therapeutics a private or public company?

    Rein Therapeutics is a Public company.

  • What is Rein Therapeutics’s stock symbol?

    The ticker symbol for Rein Therapeutics is RNTX.

  • What is the current stock price of Rein Therapeutics?

    As of 19-Nov-2026 the stock price of Rein Therapeutics is $0.36.

  • What is the current market cap of Rein Therapeutics?

    The current market capitalization of Rein Therapeutics is $31.7M.

  • Who are Rein Therapeutics’s competitors?

    Inovio Pharmaceuticals, Phathom Pharmaceuticals, XBiotech, Zealand Pharma, and Xenetic Biosciences are some of the 115 competitors of Rein Therapeutics.

  • What is Rein Therapeutics’s annual earnings per share (EPS)?

    Rein Therapeutics’s EPS for 12 months was -$1.51.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process